Hansa Biopharma AB (publ) (HNSBF)
USD 3.0
(0.0%)
USD 3.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 866.76 Million SEK | 9.57% |
| 2022 | 791.09 Million SEK | 2136.05% |
| 2021 | 35.37 Million SEK | 601.27% |
| 2020 | 5.04 Million SEK | -46.66% |
| 2019 | 9.45 Million SEK | 1539.34% |
| 2018 | 577 Thousand SEK | 43.18% |
| 2017 | 403 Thousand SEK | 739.58% |
| 2016 | 48 Thousand SEK | -47.25% |
| 2015 | 91 Thousand SEK | -30.0% |
| 2014 | 130 Thousand SEK | -74.94% |
| 2013 | 518.72 Thousand SEK | 154.28% |
| 2012 | 204 Thousand SEK | -93.06% |
| 2011 | 2.93 Million SEK | 0.0% |
| 2010 | - SEK | -100.0% |
| 2009 | 8 Million SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 947.12 Million SEK | 9.27% |
| 2024 Q2 | 974.48 Million SEK | 2.89% |
| 2024 Q3 | 942.95 Million SEK | -1.57% |
| 2023 Q4 | 866.76 Million SEK | -6.78% |
| 2023 FY | 866.76 Million SEK | 9.57% |
| 2023 Q1 | 824.4 Million SEK | 4.21% |
| 2023 Q2 | 865.84 Million SEK | 5.03% |
| 2023 Q3 | 929.81 Million SEK | 7.39% |
| 2022 Q1 | 33.67 Million SEK | -4.81% |
| 2022 Q2 | 31.94 Million SEK | -5.15% |
| 2022 FY | 791.09 Million SEK | 2136.05% |
| 2022 Q3 | 791.01 Million SEK | 2376.34% |
| 2022 Q4 | 791.09 Million SEK | 0.01% |
| 2021 Q2 | 21.51 Million SEK | 458.54% |
| 2021 Q1 | 3.85 Million SEK | -23.65% |
| 2021 FY | 35.37 Million SEK | 601.27% |
| 2021 Q3 | 20.16 Million SEK | -6.26% |
| 2021 Q4 | 35.37 Million SEK | 75.41% |
| 2020 Q1 | 8.56 Million SEK | -9.47% |
| 2020 Q4 | 5.04 Million SEK | -18.98% |
| 2020 Q3 | 6.22 Million SEK | -15.85% |
| 2020 Q2 | 7.4 Million SEK | -13.58% |
| 2020 FY | 5.04 Million SEK | -46.66% |
| 2019 Q3 | 39.69 Million SEK | 17.52% |
| 2019 Q1 | 15.22 Million SEK | 2538.82% |
| 2019 Q2 | 33.77 Million SEK | 121.83% |
| 2019 FY | 9.45 Million SEK | 1539.34% |
| 2019 Q4 | 9.45 Million SEK | -76.17% |
| 2018 Q4 | 577 Thousand SEK | -50.98% |
| 2018 Q2 | 668 Thousand SEK | 2.45% |
| 2018 Q1 | 652 Thousand SEK | 61.79% |
| 2018 FY | 577 Thousand SEK | 43.18% |
| 2018 Q3 | 1.17 Million SEK | 76.2% |
| 2017 Q3 | 592 Thousand SEK | -0.34% |
| 2017 Q2 | 594 Thousand SEK | -0.5% |
| 2017 Q1 | 597 Thousand SEK | 1143.75% |
| 2017 FY | 403 Thousand SEK | 739.58% |
| 2017 Q4 | 403 Thousand SEK | -31.93% |
| 2016 Q3 | 591 Thousand SEK | 1274.42% |
| 2016 Q4 | 48 Thousand SEK | -91.88% |
| 2016 FY | 48 Thousand SEK | -47.25% |
| 2016 Q2 | 43 Thousand SEK | 2.38% |
| 2016 Q1 | 42 Thousand SEK | -53.85% |
| 2015 Q1 | 5.12 Million SEK | 3839.23% |
| 2015 Q2 | 41 Thousand SEK | -99.2% |
| 2015 Q4 | 91 Thousand SEK | 121.95% |
| 2015 Q3 | 41 Thousand SEK | 0.0% |
| 2015 FY | 91 Thousand SEK | -30.0% |
| 2014 Q4 | 130 Thousand SEK | 0.0% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 FY | 130 Thousand SEK | -74.94% |
| 2014 Q2 | - SEK | 0.0% |
| 2013 Q4 | 518.72 Thousand SEK | -20.2% |
| 2013 FY | 518.72 Thousand SEK | 154.28% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q3 | 650 Thousand SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q4 | 204 Thousand SEK | 0.0% |
| 2012 FY | 204 Thousand SEK | -93.06% |
| 2011 Q4 | 2.93 Million SEK | 0.0% |
| 2011 FY | 2.93 Million SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 FY | - SEK | -100.0% |
| 2009 FY | 8 Million SEK | 0.0% |
| 2009 Q4 | 8 Million SEK | 0.0% |
| 2009 Q2 | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| 2008 Q4 | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -339021.725% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -64411.635% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -70462.97% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -1898.405% |
| GB Sciences, Inc. | 1.75 Million USD | -49167.581% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | 4.61 Million USD | -18680.456% |
| Zenith Capital Corp. | 10.22 Thousand USD | -8476848.655% |
| Agentix Corp. | 50 Thousand USD | -1733436.0% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -14663.323% |
| Biomind Labs Inc. | 735.54 Thousand USD | -117740.722% |
| ContraFect Corporation | 2.88 Million USD | -29985.665% |
| CSL Limited | 12.18 Billion USD | 92.885% |
| CytoDyn Inc. | 30.07 Million USD | -2781.926% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -240862.998% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -137465.409% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -1802.476% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -91305.094% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -114520.922% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -2811.828% |
| SQZ Biotechnologies Company | 27.47 Million USD | -3055.211% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -97501.975% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -2003.653% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -37165.037% |
| Mesoblast Limited | 118.7 Million USD | -630.215% |
| Marizyme, Inc. | 18.71 Million USD | -4530.791% |
| Genus plc | 233.1 Million USD | -271.844% |
| Pharming Group N.V. | 171.54 Million USD | -405.272% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -115469.067% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -59829.241% |
| IMV Inc. | 28.88 Million USD | -2900.869% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -15218.38% |
| MultiCell Technologies, Inc. | 202.58 USD | -427864447.339% |
| ONE Bio Corp. | 19.71 Million USD | -4296.485% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -1407.711% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -2518.555% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -28542.211% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -6568.988% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -612378.978% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -3370046.584% |
| Alpha Cognition Inc. | 1.22 Million USD | -70924.901% |
| Enzolytics Inc. | 996.33 Thousand USD | -86895.377% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | -4233.84% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -12154.931% |
| Genscript Biotech Corporation | 417.73 Million USD | -107.491% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -20928.07% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -215594.95% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -36049.615% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -377920.943% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -582977.482% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -29478.609% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -639642.558% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -57887.451% |
| Q BioMed Inc. | 4.1 Million USD | -20989.343% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -4163.912% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -1181.389% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | -18297.183% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -38280.061% |
| HST Global, Inc. | 98.31 Thousand USD | -881487.486% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -348391.476% |
| Halberd Corporation | 150 Thousand USD | -577745.333% |
| Resverlogix Corp. | 6.49 Million USD | -13253.382% |
| Cell Source, Inc. | 9.25 Million USD | -9266.238% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -31899.374% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -431953.276% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | -39300.695% |
| Kadimastem Ltd | 891.22 Thousand USD | -97155.69% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -410739.199% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -346354.981% |
| LadRx Corporation | 33.6 Thousand USD | -2579106.094% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -114520.922% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -379433.841% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -17294.501% |
| Mobile Lads Corp. | 484.28 Thousand USD | -178879.277% |
| International Stem Cell Corporation | 4.17 Million USD | -20646.003% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 1.92 Million USD | -44926.909% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -246247.986% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -10984.046% |
| SYBLEU INC | 477.5 Thousand USD | -181422.094% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -707465.714% |
| Rebus Holdings, Inc. | 310 Thousand USD | -279502.581% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -18204.464% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1388661.957% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -39643.592% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -10322.896% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -9996.308% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -55623.542% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -323320.896% |
| Neutra Corp. | 54.15 Thousand USD | -1600402.253% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -47264.372% |
| PureTech Health plc | 25.51 Million USD | -3297.491% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -70701.306% |
| IXICO plc | 472.02 Thousand USD | -183528.34% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -5491.691% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -1292.108% |
| CSL Limited | 12.18 Billion USD | 92.885% |
| Cellectis S.A. | 92.77 Million USD | -834.254% |